浏览全部资源
扫码关注微信
1.广州中医药大学 第一附属医院,广州 510405
2.重庆市中医院,重庆 400021
涂海涛,博士,从事慢性肾脏病基础与临床研究,Tel:020-36591358,E-mail:124169731@qq.com
黎颖,博士,副主任医师,从事中西医结合防治慢性肾脏病及中药药理学相关研究,Tel:023-67983680,E-mail:sabrina_pipi@163.com
收稿日期:2021-08-24,
网络出版日期:2022-03-11,
纸质出版日期:2022-05-05
移动端阅览
涂海涛,黎颖,宋娜等.健脾养阴固涩方对糖尿病肾病气阴两虚证患者临床疗效及足细胞的保护作用[J].中国实验方剂学杂志,2022,28(09):103-109.
TU Hai-tao,LI Ying,SONG Na,et al.Clinical Effect of Jianpi Yangyin Guse Decoction on Podocin and Nephrin and Its Protection Against Podocyte Injury in Diabetic Nephropathy Patients with Qi and Yin Deficiency[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(09):103-109.
涂海涛,黎颖,宋娜等.健脾养阴固涩方对糖尿病肾病气阴两虚证患者临床疗效及足细胞的保护作用[J].中国实验方剂学杂志,2022,28(09):103-109. DOI: 10.13422/j.cnki.syfjx.20220994.
TU Hai-tao,LI Ying,SONG Na,et al.Clinical Effect of Jianpi Yangyin Guse Decoction on Podocin and Nephrin and Its Protection Against Podocyte Injury in Diabetic Nephropathy Patients with Qi and Yin Deficiency[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(09):103-109. DOI: 10.13422/j.cnki.syfjx.20220994.
目的
2
观察健脾养阴固涩方对糖尿病肾病(DN)患者的临床疗效及对足细胞的保护作用。
方法
2
选取2017年1月至2020年1月收治的DN Ⅲ和Ⅳ期、辨证为气阴两虚证患者120例,随机分为观察组和对照组,另招募正常组20例。两组给予基础治疗,观察组在对照组基础上加服健脾养阴固涩方中药汤剂,经过3个月治疗,检测中医症型积分、24 h尿蛋白定量(24 h UP)、尿微量白蛋白/尿肌酐(UACR)、肝肾功能、
D
-二聚体、糖化血红蛋白(HbA1C)、尿液中足细胞裂孔膜蛋白(Nephrin)、膜蛋白(Podocin)、
α
-平滑肌肌动蛋白(
α
-SMA)排泄量的变化情况,并与正常组进行比较,进行统计分析。
结果
2
观察组的中医症型积分在治疗后显著优于对照组(
P
<
0.01)。观察组治疗后第2、3个月24 h UP、UACR和肾功能水平较同组治疗前均显著下降,观察组治疗后第3个月24 h UP、UACR和肾功能水平明显低于同期对照组(
P
<
0.05)。观察组治疗后各月的Podocin、Nephrin排泄量和第2、3个月
α
-SMA水平较同组治疗前下调;与对照组比较,观察组治疗后各月的Podocin、Nephrin排泄量和第3个月
α
-SMA水平下调(
P
<
0.05)。治疗前后两组患者的安全性指标
D
-二聚体和肝功能无明显变化,差异无统计学意义;HbA1C水平观察组治疗后较对照组上调(
P
<
0.05)。
结论
2
健脾养阴固涩方对DN患者具有良好的临床疗效,其作用机制可能与下调足细胞标志蛋白Podocin、Nephrin和
α
-SMA排泄量有关。
Objective
2
To observe the clinical effect of Jianpi Yangyin Guse decoction on patients with diabetic nephropathy (DN),and to explore its protection against podocyte injury.
Method
2
The enrolled 120 DN patients at stages Ⅲ and Ⅳ and diagnosed with Qi and Yin deficiency from January 2017 to January 2020 were randomly divided into observation group and control group. During the same period,20 healthy volunteers were recruited as the normal group. In addition to the basic treatment in control group,patients in the observation group were given Jianpi Yangyin Guse decoction,and the course of treatment lasted for 3 months. The traditional Chinese medicine (TCM)syndrome score,24 h urine protein (24 h UP),urine albumin-to-creatinine ratio(UACR),liver and renal functions,
D
-dimer, hemoglobin A1c (HbA1c), urine podocin and nephrin and
α
-smooth muscle actin (
α
-SMA) excretion of the two groups were observed before and after treatment,and the changes were statistically analyzed and compared with those in the normal group.
Result
2
After treatment,the reduction of TCM syndrome score in the observation group was more significant than that in the control group(
P
<
0.01). The 24 h UP level,UACR and renal function in the observation group in the 2nd and 3rd months after treatment were lower than the conditions before treatment(
P
<
0.05), and those in the 3
rd
month after treatment were decreased compared with the conditions in the control group during the same period. The levels of podocin and nephrin in each month and the
α
-SMA excretion in the 3rd month after treatment in the observation group were down-regulated compared with the conditions before treatment and in the control group (
P
<
0.05), and the observation group had reduced
α
-SMA excretion in the 2nd month after treatment compared with before treatment. There were no marked changes in
D
-dimer and liver function of the two groups before and after treatment. The level of HbA1c in the observation group was higher than that in the control group after treatment(
P
<
0.05).
Conclusion
2
Jianpi Yangyin Guse decoction has desirable clinical efficacy in DN patients,and its mechanism may be related to reducing podocin and nephrin and
α
-SMA excretion levels.
陆菊明 . 中国2型糖尿病防治指南(2013年版)编写说明 [J]. 中国糖尿病杂志 , 2014 , 22 ( 8 ): 后插1 .
ROOINTAN A , GHEISARI Y , HUDKINS K L , et al . Non-invasive metabolic biomarkers for early diagnosis of diabetic nephropathy: Meta-analysis of profiling metabolomics studies [J]. Nutr Metab Cardiovasc Dis , 2021 , 31 ( 8 ): 2253 - 2272 .
NATESAN V , KIM S J . Diabetic Nephropathy - a review of risk factors, progression, mechanism, and dietary management [J]. Biomol Ther (Seoul) , 2021 , 29 ( 4 ): 365 - 372 .
吕树泉 , 路菲菲 , 苏秀海 , 等 . 三黄益肾胶囊防治糖尿病肾病实验研究 [J]. 世界中医药 , 2021 , 16 ( 3 ): 443 - 448 .
吕翠岩 , 张岩 , 贾晓蕾 , 等 . 参芪地黄汤化裁方结合西医常规疗法治疗Ⅳ期糖尿病肾病临床研究 [J]. 国际中医中药杂志 , 2020 , 42 ( 5 ): 431 - 436 .
陈刚毅 , 苏保林 , 李鑫 . 益气养阴祛瘀法治疗糖尿病肾病气阴两虚夹瘀证的疗效及对Th17、Th22细胞因子的调节作用 [J]. 中华中医药学刊 , 2019 , 37 ( 3 ): 669 - 672 .
宫成军 , 马晓燕 . 基于网络药理学探讨肾衰饮治疗糖尿病肾病的作用机制 [J]. 世界中医药 , 2021 , 16 ( 8 ): 1214 - 1220 .
赵洪泉 . 益肾通络泄毒方治疗早期糖尿病肾病临床观察 [J]. 光明中医 , 2019 , 34 ( 12 ): 1791 - 1792 .
朱凤齐 , 李帅 , 肖俭 , 等 . 益气养阴活血汤治疗糖尿病肾病气阴两虚兼血瘀证53例 [J]. 中医研究 , 2019 , 32 ( 8 ): 16 - 18 .
张婧 , 李靖 , 张海力 , 等 . 尿毒清颗粒联合血管紧张素系统阻滞剂治疗糖尿病肾病的Meta分析 [J]. 世界中医药 , 2021 , 16 ( 2 ): 274 - 273 .
刘晴 , 蔡倩 , 王暴魁 . 基于足细胞保护探讨中医药治疗糖尿病肾病作用机制的实验研究进展 [J]. 环球中医药 , 2021 ,( 14 ) 1 : 169 - 172 .
WANG R M , WANG Z B , WANG Y , et al . Swiprosin-1 promotes mitochondria-dependent apoptosis of glomerular podocytes via P38 MAPK pathway in early-stage diabetic nephropathy [J]. Cell Physiol Biochem , 2018 , 45 ( 3 ): 899 - 916 .
曹芸 , 冯俊 , 丁国华 . 线粒体内质网耦联在糖尿病肾病足细胞损伤中的作用及机制 [J]. 中华肾脏病杂志 , 2021 , 37 ( 1 ): 59 - 64 .
王超 , 杨翠 , 汤水福 , 等 . 升清降浊胶囊对慢性肾脏疾病3~5期非透析患者中医症状的改善作用及对患者肾功能的影响 [J]. 河北中医 , 2018 , 40 ( 6 ): 821 - 826 .
余燕娜 , 汤水福 . 升清降浊胶囊治疗慢性肾衰竭脾肾气虚湿浊证的临床研究 [J]. 中国中西医结合肾病杂志 , 2018 , 19 ( 7 ): 608 - 610 .
苏保林 , 陈刚毅 , 汤水福 . 升清降浊胶囊对STZ诱导糖尿病肾病大鼠肾脏VEGF表达及肾功能的影响 [J]. 中国中西医结合肾病杂志 , 2017 , 18 ( 10 ): 876 - 878, 后插2.
中华医学会糖尿病学分会 . 中国2型糖尿病防治指南(2010年版) [J]. 中国糖尿病杂志 , 2012 , 20 ( 1 ): 81 - 117 .
王海燕 . 肾脏病学 [M]. 3版 . 北京 : 人民卫生出版社 , 2009 : 1423 - 1424 .
中华中医药学会肾病分会 . 糖尿病神兵诊断、辨证分型及疗效评定标准(试行方案) [J]. 上海中医药杂志 , 2007 , 41 ( 7 ): 7 - 8 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 56 - 162 .
ROCA-HO H , PALAU V , GIMENO J , et al . Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice [J]. Lab Invest , 2020 , 100 ( 9 ): 1169 - 1183 .
CHEN Z , MA Y , YANG Q , et al . AKAP1 mediates high glucose-induced mitochondrial fission through the phosphorylation of Drp1 in podocytes [J]. J Cell Physiol , 2020 , 235 ( 10 ): 7433 - 7448 .
ROGACKA D , AUDZEYENKA I , PIWKOWSKA A . Regulation of podocytes function by AMP-activated protein kinase [J]. Arch Biochem Biophys , 2020 , 692 : 108541 .
JIANG L , CUI H , DING J . Smad3 signalling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin [J]. Nephrology (Carlton) , 2020 , 25 ( 9 ): 659 - 666 .
WANG Q L , SHEN Z W , QI G H , et al . Thymo alleviates AGEs-induced podocyte injury by a pleiotropic effect via NF- κ B-mediated by RhoA/ROCK signalling pathway [J]. Cell Adh Migr , 2020 , 14 ( 1 ): 42 - 56 .
QI X M , WANG J , XU X X , et al . FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats [J]. Inflamm Res , 2016 , 65 ( 2 ): 103 - 114 .
徐蕾 , 任现志 . 黄芪甲苷通过抑制PKC/MAPK通路修复损伤人足细胞裂孔膜 [J]. 南京中医药大学学报 , 2018 , 34 ( 3 ): 303 - 306 .
宋志霞 , 饶毅峰 , 刘阳 , 等 . 黄芪甲苷对糖尿病肾病大鼠足细胞裂孔隔膜的保护作用 [J]. 西部中医药 , 2020 , 33 ( 1 ): 13 - 18 .
王晶 , 张晓东 , 方敬爱 , 等 . 芡实含药血清对高糖干预小鼠肾小球足细胞nephrin与 α -SMA的影响 [J]. 中国中西医结合肾病杂志 , 2016 , 17 ( 10 ): 888 - 890 .
0
浏览量
25
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构